PMID- 38250075
OWN - NLM
STAT- MEDLINE
DCOM- 20240123
LR  - 20240403
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Expert consensus on the use of systemic glucocorticoids for managing 
      eosinophil-related diseases.
PG  - 1310211
LID - 10.3389/fimmu.2023.1310211 [doi]
LID - 1310211
AB  - Eosinophil-related diseases represent a group of pathologic conditions with 
      highly heterogeneous clinical presentation and symptoms ranging from mild to 
      critical. Both systemic and localized forms of disease are typically treated with 
      glucocorticoids. The approval of novel biologic therapies targeting the 
      interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) 
      in eosinophilic diseases and reduce the risk of SGC-related adverse effects 
      (AEs). In this article, a panel of experts from different medical specialties 
      reviewed current evidence on the use of SGC in two systemic eosinophilic 
      diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and 
      HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) 
      eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and 
      Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their 
      experience in clinical practice. Using nominal group technique, they reached 
      consensus on key aspects related to the dose and tapering of SGC as well as on 
      the initiation of biologics as SGC-sparing agents. Early treatment with biologics 
      could help prevent AEs associated with medium and long-term use of SGC.
CI  - Copyright (c) 2024 del Pozo, Bobolea, Rial, Espigol-Frigole, Solans Laque, 
      Hernandez-Rivas, Mora, Crespo-Lessmann, Izquierdo Alonso, Dominguez Sosa, 
      Maza-Solano, Atienza-Mateo, Banas-Conejero, Moure and Rua-Figueroa.
FAU - Del Pozo, Victoria
AU  - Del Pozo V
AD  - Immunology Department, Instituto de Investigacion Sanitaria Fundacion Jimenez 
      Diaz (IIS-FJD), Madrid, Spain.
FAU - Bobolea, Irina
AU  - Bobolea I
AD  - Allergy Department, Severe Asthma Unit, Hospital Clinic Barcelona, Barcelona, 
      Spain.
FAU - Rial, Manuel J
AU  - Rial MJ
AD  - Allergy Department, Severe Asthma Unit, Complexo Hospitalario Universitario A 
      Coruna, A Coruna, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), 
      A Coruna, Spain.
FAU - Espigol-Frigole, Georgina
AU  - Espigol-Frigole G
AD  - Department of Autoimmune Diseases, Hospital Clinic Clinic, University of 
      Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), 
      Barcelona, Spain.
FAU - Solans Laque, Roser
AU  - Solans Laque R
AD  - Autoimmune Systemic Diseases Unit, Internal Medicine Department, Vall d'Hebron 
      Hospital, Autonomous University of Barcelona, Barcelona, Spain.
FAU - Hernandez-Rivas, Jesus Maria
AU  - Hernandez-Rivas JM
AD  - Department of Medicine, University of Salamanca & Servicio de Hematologia, 
      Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de 
      Salamanca (IBSAL), Salamanca, Spain.
FAU - Mora, Elvira
AU  - Mora E
AD  - Hematology Department, La Fe University and Polytechnic Hospital, La Fe Research 
      Institute, Valencia, Spain.
FAU - Crespo-Lessmann, Astrid
AU  - Crespo-Lessmann A
AD  - Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, 
      Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Izquierdo Alonso, Jose Luis
AU  - Izquierdo Alonso JL
AD  - Department of Medicine and Medical Specialties, University of Alcala, Alcala de 
      Henares, Madrid, Spain.
AD  - Pulmonology Service, Guadalajara University Hospital, Guadalajara, Spain.
FAU - Dominguez Sosa, Maria Sandra
AU  - Dominguez Sosa MS
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, University 
      Hospital of Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain.
FAU - Maza-Solano, Juan
AU  - Maza-Solano J
AD  - Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen 
      Macarena University Hospital, Sevilla, Spain.
FAU - Atienza-Mateo, Belen
AU  - Atienza-Mateo B
AD  - Division of Rheumatology, University Hospital of Marques de Valdecilla, Instituto 
      de Investigacion Marques de Valdecilla (IDIVAL), Immunopathology group, 
      Santander, Spain.
FAU - Banas-Conejero, David
AU  - Banas-Conejero D
AD  - Specialty Care Medical Department, GSK, Madrid, Spain.
FAU - Moure, Abraham L
AU  - Moure AL
AD  - Specialty Care Medical Department, GSK, Madrid, Spain.
FAU - Rua-Figueroa, Inigo
AU  - Rua-Figueroa I
AD  - Rheumatology Department, University Hospital of Gran Canaria Dr. Negrin, Las 
      Palmas de Gran Canaria, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20240105
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Glucocorticoids)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - Glucocorticoids/adverse effects
MH  - *Churg-Strauss Syndrome
MH  - Consensus
MH  - Eosinophils
MH  - *Granulomatosis with Polyangiitis
MH  - *Leukocyte Disorders
MH  - *Biological Products
PMC - PMC10796442
OTO - NOTNLM
OT  - adverse events
OT  - biologics
OT  - eosinophilic diseases
OT  - systemic glucocorticoids
OT  - tapering
OT  - treatment optimisation
COIS- VP has received consulting, speaker fees, grants and support to attend 
      international congresses from AstraZeneca, GSK and Sanofi. IB has received fees 
      from GSK, Novartis, Sanofi, AstraZeneca and Teva for talks at scientific events 
      and as member of advisory boards. MJR has received lecture fees from Novartis, 
      GSK, LETI, Astra-Zeneca, Chiesi and TEVA. GE-F has received consulting fees from 
      GSK and Janssen and support to attend congress from Boehringer Ingelheim. RSL has 
      received consulting fees from GSK and support to attend congresses from Menarini. 
      JMH-R has received honoraria from Amgen, Novartis, Celgene/BMS, Pfizer and GSK 
      and is a member of Novartis, Pfizer, Amgen and Celgene/BMS advisory boards. He 
      has received consulting fees from GSK and research support from Novartis and 
      Celgene/BMS. EM has received consulting fees from GSK. AC-L has received fees in 
      the last 3 years for talks at meetings sponsored by AstraZeneca, Bial, Boehringer 
      Ingelheim, Chiesi, Ferrer, GlaxoSmithKline, MSD, Novartis, Orion Pharma, and 
      Sanofi; travel and attendance expenses for conferences from Bial, Gebro, 
      GlaxoSmithKline, Novartis, and TEVA; and funds/grants for research projects from 
      several state agencies, non-profit foundations, and AstraZeneca and 
      GlaxoSmithKline. JLIA has received fees for consultancy, projects, and talks from 
      AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, Glaxo, Grifols, Smith Kline, 
      Menarini, Novartis, Orion, Pfizer, Sandoz, and Teva. MSDS has received fees from 
      GSK, Sanofi, MSD and MEDA for talks at scientific events and is a member of 
      advisory boards. JM-S has received fees from GSK, Sanofi, AstraZeneca and Teva 
      for talks at scientific events and as member of advisory boards. BA-M has 
      received grants and research support from Abbvie and Roche, and fees for 
      consulting or participating in company-sponsored speakers bureaus from GSK, 
      Boehringer Ingelheim and Janssen. DB-C and ALM are employees of GSK and hold 
      stocks/shares in GSK. IR-F: has received consulting fees from GSK and is on GSK's 
      advisory board for mepolizumab.
EDAT- 2024/01/22 06:42
MHDA- 2024/01/23 06:43
PMCR- 2023/01/01
CRDT- 2024/01/22 05:12
PHST- 2023/10/09 00:00 [received]
PHST- 2023/12/11 00:00 [accepted]
PHST- 2024/01/23 06:43 [medline]
PHST- 2024/01/22 06:42 [pubmed]
PHST- 2024/01/22 05:12 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1310211 [doi]
PST - epublish
SO  - Front Immunol. 2024 Jan 5;14:1310211. doi: 10.3389/fimmu.2023.1310211. 
      eCollection 2023.